

# **Summary of risk management plan for ELETRIPTAN ORION 20 MG AND 40 MG FILM-COATED TABLETS (ELETRIPTAN HYDROBROMIDE) Orion Corporation**

**DATE: 20-06-2022, VERSION 2.0**

---

This is a summary of the risk management plan (RMP) for Eletriptan Orion. The RMP details important risks of Eletriptan Orion, how these risks can be minimized, and how more information will be obtained about Eletriptan Orion's risks and uncertainties (missing information).

Eletriptan Orion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Eletriptan Orion should be used.

Important new concerns or changes to the current ones will be included in updates of Eletriptan Orion's RMP.

## **I. The medicine and what it is used for**

Eletriptan Orion is authorised for adults for the acute treatment of the headache phase of migraine attacks, with or without aura (see SmPC for the full indication). It contains eletriptan hydrobromide as the active substance and it is given by mouth.

## **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Eletriptan Orion, together with measures to minimise such risks and the proposed studies for learning more about Eletriptan Orion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

### **II.A List of important risks and missing information**

Important risks of Eletriptan Orion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Eletriptan Orion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

### **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### **II.C Post-authorisation development plan**

There are no studies required for Eletriptan Orion.